ERBB2 and breast carcinoma: Our results demonstrate that an anti‐SorLA antibody (SorLA ab) alters the resistance of metastatic breast cancer cells to the HER2 monoclonal antibody trastuzumab in vitro and in chick chorioallantoic membrane (CAM) assays.